FBDIX: Franklin Biotechnology Discovery Fund - MutualFunds.com
Continue to site >
Trending ETFs

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.
Not interested

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Franklin Biotechnology Discovery A

FBDIX - Snapshot

Vitals

  • YTD Return -2.8%
  • 3 Yr Annualized Return 9.2%
  • 5 Yr Annualized Return 9.5%
  • Net Assets $1.45 B
  • Holdings in Top 10 42.3%

52 WEEK LOW AND HIGH

$165.88
$149.16
$198.29

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.03%

SALES FEES

  • Front Load 5.50%
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 32.92%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $1,000
  • IRA $250

Fund Classification

Compare FBDIX to Popular Health Care Sector Equity Funds and ETFs

Overview

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Vanguard Health Care Fund

Fund

$234.60

+0.07%

$49.75 B

0.92%

$2.16

8.76%

0.32%

Health Care Select Sector SPDR® Fund

XLV | ETF

$124.70

+0.03%

$27.65 B

1.37%

$1.70

9.93%

0.13%

T. Rowe Price Health Sciences Fund

Fund

$106.14

+0.09%

$18.04 B

-

$0.00

7.37%

0.76%

Vanguard Health Care Index Fund

Fund

$122.16

+0.11%

$17.26 B

1.19%

$1.45

9.16%

0.10%

Vanguard Health Care Index Fund

VHT | ETF

$244.31

+0.11%

$17.26 B

1.19%

$2.90

8.82%

0.10%

FBDIX - Profile

Distributions

  • YTD Total Return -2.8%
  • 3 Yr Annualized Total Return 7.1%
  • 5 Yr Annualized Total Return 8.3%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.49%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Franklin Biotechnology Discovery Fund
  • Fund Family Name
    Franklin Templeton Investments
  • Inception Date
    Sep 15, 1997
  • Shares Outstanding
    7030273
  • Share Class
    A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Evan McCulloch

Fund Description

Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

FBDIX - Performance

Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
YTD -2.8% -11.8% 26.8% 93.02%
1 Yr 6.7% -1.4% 110.6% 98.81%
3 Yr 9.2%* 3.2% 43.8% 92.57%
5 Yr 9.5%* 3.7% 37.4% 89.36%
10 Yr 14.2%* 8.4% 18.8% 56.10%

* Annualized

Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
2020 13.6% -13.6% 178.2% 54.04%
2019 23.3% 3.8% 63.8% 31.72%
2018 -18.6% -49.7% 21.5% 91.24%
2017 16.0% -59.8% 54.4% 59.26%
2016 -20.7% -36.6% 11.6% 78.91%

Total Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
YTD -2.8% -11.8% 26.8% 94.77%
1 Yr 0.8% -1.4% 110.6% 99.40%
3 Yr 7.1%* 3.2% 43.8% 96.62%
5 Yr 8.3%* 3.7% 37.4% 90.78%
10 Yr 13.6%* 8.4% 18.8% 64.23%

* Annualized

Total Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
2020 13.6% -13.6% 178.2% 54.04%
2019 23.3% 3.8% 63.8% 31.72%
2018 -18.6% -25.3% 22.2% 92.70%
2017 18.8% -10.8% 54.4% 62.22%
2016 -17.1% -36.6% 11.6% 72.66%

NAV & Total Return History

FBDIX - Holdings

Concentration Analysis

FBDIX Category Low Category High FBDIX % Rank
Net Assets 1.45 B 6.68 M 49.7 B 41.62%
Number of Holdings 110 25 506 41.62%
Net Assets in Top 10 613 M 1.53 M 19.3 B 39.31%
Weighting of Top 10 42.30% 8.9% 78.2% 32.37%

Top 10 Holdings

  1. Gilead Sciences Inc 6.08%
  2. Regeneron Pharmaceuticals Inc 6.06%
  3. Regeneron Pharmaceuticals Inc 6.06%
  4. Regeneron Pharmaceuticals Inc 6.06%
  5. Regeneron Pharmaceuticals Inc 6.06%
  6. Regeneron Pharmaceuticals Inc 6.06%
  7. Regeneron Pharmaceuticals Inc 6.06%
  8. Regeneron Pharmaceuticals Inc 6.06%
  9. Regeneron Pharmaceuticals Inc 6.06%
  10. Regeneron Pharmaceuticals Inc 6.06%

Asset Allocation

Weighting Return Low Return High FBDIX % Rank
Stocks 		95.63% 82.66% 105.23% 85.55%
Cash 		3.78% -0.13% 17.34% 8.09%
Other 		0.59% -26.63% 8.98% 23.70%
Preferred Stocks 		0.00% 0.00% 5.58% 13.87%
Convertible Bonds 		0.00% 0.00% 0.02% 4.05%
Bonds 		0.00% 0.00% 18.37% 6.36%

Stock Sector Breakdown

Weighting Return Low Return High FBDIX % Rank
Healthcare 		98.30% 63.71% 100.00% 74.57%
Financial Services 		1.70% 0.00% 3.21% 4.62%
Utilities 		0.00% 0.00% 0.00% 3.47%
Technology 		0.00% 0.00% 19.82% 16.18%
Real Estate 		0.00% 0.00% 6.18% 10.40%
Industrials 		0.00% 0.00% 6.41% 14.45%
Energy 		0.00% 0.00% 0.00% 3.47%
Communication Services 		0.00% 0.00% 8.10% 7.51%
Consumer Defense 		0.00% 0.00% 29.47% 10.98%
Consumer Cyclical 		0.00% 0.00% 14.16% 12.72%
Basic Materials 		0.00% 0.00% 3.71% 36.42%

Stock Geographic Breakdown

Weighting Return Low Return High FBDIX % Rank
US 		90.94% 58.55% 101.51% 22.54%
Non US 		4.69% 0.00% 40.32% 80.92%

FBDIX - Expenses

Operational Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.03% 0.08% 7.05% 49.70%
Management Fee 0.60% 0.00% 1.25% 35.43%
12b-1 Fee 0.25% 0.00% 1.00% 21.05%
Administrative Fee 0.15% 0.03% 0.25% 60.98%

Sales Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load 5.50% 3.50% 5.75% 56.52%
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 32.92% 3.00% 256.00% 28.40%

FBDIX - Distributions

Dividend Yield Analysis

FBDIX Category Low Category High FBDIX % Rank
Dividend Yield 0.00% 0.00% 0.95% 16.57%

Dividend Distribution Analysis

FBDIX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

FBDIX Category Low Category High FBDIX % Rank
Net Income Ratio -0.49% -2.54% 1.74% 79.41%

Capital Gain Distribution Analysis

FBDIX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Dividend Payout History

View More +

FBDIX - Fund Manager Analysis

Managers

Evan McCulloch

Start Date

Tenure

Tenure Rank

Sep 15, 1997

23.72

23.7%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.

Wendy Lam

Start Date

Tenure

Tenure Rank

Sep 01, 2018

2.75

2.8%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.

Akiva Felt

Start Date

Tenure

Tenure Rank

Jan 27, 2020

1.34

1.3%

Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.04 23.72 7.22 21.1

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.